{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:08:03Z","timestamp":1751429283888,"version":"3.41.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021MH079"],"award-info":[{"award-number":["ZR2021MH079"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82104917"],"award-info":[{"award-number":["82104917"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key Project of Medicine and Health of Shandong Province","award":["202312070996"],"award-info":[{"award-number":["202312070996"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14350-2","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:16:39Z","timestamp":1751354199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetically proxied therapeutic effect of antihypertensive drug use, breast cancer, and ovarian cancer\u2019s risk: a drug-target Mendelian randomization study"],"prefix":"10.1186","volume":"25","author":[{"given":"Chunxiao","family":"Dang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruohan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunzhen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongxu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"14350_CR1","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","volume":"389","author":"N Harbeck","year":"2017","unstructured":"Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389:1134\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(16)31891-8.","journal-title":"Lancet"},{"key":"14350_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"14350_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/IJWH.S197604","volume":"11","author":"Z Momenimovahed","year":"2019","unstructured":"Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287\u201399. https:\/\/doi.org\/10.2147\/IJWH.S197604.","journal-title":"Int J Womens Health"},{"key":"14350_CR4","unstructured":"American Cancer Society. Cancer Facts & Figs. 2024. Atlanta: American Cancer Society; 2024."},{"key":"14350_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/HYPERTENSIONAHA.120.16044","volume":"77","author":"S Kidoguchi","year":"2021","unstructured":"Kidoguchi S, Sugano N, Tokudome G, Yokoo T, Yano Y, Hatake K, et al. New concept of Onco-Hypertension and future perspectives. Hypertension. 2021;77:16\u201327. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.16044.","journal-title":"Hypertension"},{"key":"14350_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/HJH.0000000000002591","volume":"39","author":"C Xu","year":"2021","unstructured":"Xu C. The Elabela in hypertension, cardiovascular disease, renal disease, and preeclampsia: an update. J Hypertens. 2021;39:12\u201322. https:\/\/doi.org\/10.1097\/HJH.0000000000002591.","journal-title":"J Hypertens"},{"key":"14350_CR7","doi-asserted-by":"publisher","first-page":"204062232096415","DOI":"10.1177\/2040622320964152","volume":"11","author":"P Potme\u0161il","year":"2020","unstructured":"Potme\u0161il P, Szotkowsk\u00e1 R. Drug-induced liver injury after switching from Tamoxifen to anastrozole in a patient with a history of breast cancer being treated for hypertension and diabetes. Ther Adv Chronic Dis. 2020;11:2040622320964152. https:\/\/doi.org\/10.1177\/2040622320964152.","journal-title":"Ther Adv Chronic Dis"},{"key":"14350_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41366-020-00676-3","volume":"45","author":"S Laforest","year":"2021","unstructured":"Laforest S, Ennour-Idrissi K, Ouellette G, Gauthier MF, Michaud A, Durocher F, et al. Associations between markers of mammary adipose tissue dysfunction and breast cancer prognostic factors. Int J Obes (Lond). 2021;45:195\u2013205. https:\/\/doi.org\/10.1038\/s41366-020-00676-3.","journal-title":"Int J Obes (Lond)"},{"key":"14350_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.15585\/mmwr.mm7309a1","volume":"73","author":"A Sekkarie","year":"2024","unstructured":"Sekkarie A, Fang J, Hayes D, Loustalot F. Prevalence of Self-Reported hypertension and antihypertensive medication use among Adults - United States, 2017\u20132021. MMWR Morb Mortal Wkly Rep. 2024;73:191\u20138. https:\/\/doi.org\/10.15585\/mmwr.mm7309a1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"14350_CR10","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1001\/jama.2022.19590","volume":"328","author":"RM Carey","year":"2022","unstructured":"Carey RM, Moran AE, Whelton PK. Treatment of hypertension: A review. JAMA. 2022;328:1849\u201361. https:\/\/doi.org\/10.1001\/jama.2022.19590.","journal-title":"JAMA"},{"key":"14350_CR11","doi-asserted-by":"publisher","first-page":"609901","DOI":"10.3389\/fphar.2021.609901","volume":"12","author":"Y Xie","year":"2021","unstructured":"Xie Y, Wang M, Xu P, Deng Y, Zheng Y, Yang S, et al. Association between antihypertensive medication use and breast cancer: A systematic review and Meta-Analysis. Front Pharmacol. 2021;12:609901. https:\/\/doi.org\/10.3389\/fphar.2021.609901.","journal-title":"Front Pharmacol"},{"key":"14350_CR12","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ygyno.2008.02.019","volume":"109","author":"D Herr","year":"2008","unstructured":"Herr D, Rodewald M, Fraser HM, Hack G, Konrad R, Kreienberg R, et al. Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer. Gynecol Oncol. 2008;109:418\u201325. https:\/\/doi.org\/10.1016\/j.ygyno.2008.02.019.","journal-title":"Gynecol Oncol"},{"key":"14350_CR13","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/nm1447","volume":"12","author":"PH Thaker","year":"2006","unstructured":"Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12:939\u201344. https:\/\/doi.org\/10.1038\/nm1447.","journal-title":"Nat Med"},{"key":"14350_CR14","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nrc2945","volume":"10","author":"AJ George","year":"2010","unstructured":"George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 2010;10:745\u201359. https:\/\/doi.org\/10.1038\/nrc2945.","journal-title":"Nat Rev Cancer"},{"key":"14350_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2015.05.042","volume":"193","author":"PY Pai","year":"2015","unstructured":"Pai PY, Hsieh VC, Wang CB, Wu HC, Liang WM, Chang YJ, et al. Long term antihypertensive drug use and prostate cancer risk: A 9-year population-based cohort analysis. Int J Cardiol. 2015;193:1\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2015.05.042.","journal-title":"Int J Cardiol"},{"key":"14350_CR16","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S1470-2045(21)00033-4","volume":"22","author":"E Copland","year":"2021","unstructured":"Copland E, Canoy D, Nazarzadeh M, Bidel Z, Ramakrishnan R, Woodward M, et al. Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. Lancet Oncol. 2021;22:558\u201370. https:\/\/doi.org\/10.1016\/S1470-2045(21)00033-4.","journal-title":"Lancet Oncol"},{"key":"14350_CR17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2215-0366(19)30293-7","volume":"7","author":"R Carnegie","year":"2020","unstructured":"Carnegie R, Zheng J, Sallis HM, Jones HJ, Wade KH, Evans J, et al. Mendelian randomisation for nutritional psychiatry. Lancet Psychiatry. 2020;7:208\u201316. https:\/\/doi.org\/10.1016\/S2215-0366(19)30293-7.","journal-title":"Lancet Psychiatry"},{"key":"14350_CR18","doi-asserted-by":"publisher","first-page":"k601","DOI":"10.1136\/bmj.k601","volume":"362","author":"NM Davies","year":"2018","unstructured":"Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601. https:\/\/doi.org\/10.1136\/bmj.k601.","journal-title":"BMJ"},{"key":"14350_CR19","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339.","journal-title":"Eur Heart J"},{"key":"14350_CR20","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/s41588-018-0205-x","volume":"50","author":"E Evangelou","year":"2018","unstructured":"Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet. 2018;50:1412\u201325. https:\/\/doi.org\/10.1038\/s41588-018-0205-x.","journal-title":"Nat Genet"},{"key":"14350_CR21","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41588-021-00931-x","volume":"53","author":"S Sakaue","year":"2021","unstructured":"Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S. A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet. 2021;53:1415\u201324. https:\/\/doi.org\/10.1038\/s41588-021-00931-x.","journal-title":"Nat Genet"},{"key":"14350_CR22","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1161\/CIRCULATIONAHA.118.038814","volume":"140","author":"D Gill","year":"2019","unstructured":"Gill D, Georgakis MK, Koskeridis F, Jiang L, Feng Q, Wei WQ, et al. Use of genetic variants related to antihypertensive drugs to inform on efficacy and side effects. Circulation. 2019;140:270\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038814.","journal-title":"Circulation"},{"key":"14350_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2337\/db24-0451","volume":"74","author":"DB Rosoff","year":"2025","unstructured":"Rosoff DB, Wagner J, Jung J, Pacher P, Christodoulides C, Davey Smith G, et al. Multiomic Mendelian randomization study investigating the impact of PCSK9 and HMGCR Inhibition on type 2 diabetes across five populations. Diabetes. 2025;74:120\u201330. https:\/\/doi.org\/10.2337\/db24-0451.","journal-title":"Diabetes"},{"key":"14350_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12916-021-01951-4","volume":"19","author":"JV Zhao","year":"2021","unstructured":"Zhao JV, Schooling CM. Using Mendelian randomization study to assess the renal effects of antihypertensive drugs. BMC Med. 2021;19:79. https:\/\/doi.org\/10.1186\/s12916-021-01951-4.","journal-title":"BMC Med"},{"key":"14350_CR25","doi-asserted-by":"publisher","first-page":"e353","DOI":"10.1212\/WNL.0000000000009814","volume":"95","author":"MK Georgakis","year":"2020","unstructured":"Georgakis MK, Gill D, Webb AJS, Evangelou E, Elliott P, Sudlow CLM, et al. Genetically determined blood pressure, antihypertensive drug classes, and risk of stroke subtypes. Neurology. 2020;95:e353\u201361. https:\/\/doi.org\/10.1212\/WNL.0000000000009814.","journal-title":"Neurology"},{"key":"14350_CR26","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1161\/ATVBAHA.120.315482","volume":"41","author":"MG Levin","year":"2021","unstructured":"Levin MG, Klarin D, Walker VM, Gill D, Lynch J, Hellwege JN, et al. Association between genetic variation in blood pressure and increased lifetime risk of peripheral artery disease. Arterioscler Thromb Vasc Biol. 2021;41:2027\u201334. https:\/\/doi.org\/10.1161\/ATVBAHA.120.315482.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"14350_CR27","doi-asserted-by":"publisher","first-page":"e3249","DOI":"10.1210\/clinem\/dgab097","volume":"106","author":"Z Zhuang","year":"2021","unstructured":"Zhuang Z, Yu C, Guo Y, Bian Z, Yang L, Millwood IY, et al. Metabolic signatures of genetically elevated vitamin D among Chinese: observational and Mendelian randomization study. J Clin Endocrinol Metab. 2021;106:e3249\u201360. https:\/\/doi.org\/10.1210\/clinem\/dgab097.","journal-title":"J Clin Endocrinol Metab"},{"key":"14350_CR28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12916-020-01778-5","volume":"18","author":"F Wu","year":"2020","unstructured":"Wu F, Huang Y, Hu J, Shao Z. Mendelian randomization study of inflammatory bowel disease and bone mineral density. BMC Med. 2020;18:312. https:\/\/doi.org\/10.1186\/s12916-020-01778-5.","journal-title":"BMC Med"},{"key":"14350_CR29","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1093\/ije\/dyy265","volume":"47","author":"J Bowden","year":"2018","unstructured":"Bowden J, Spiller W, Del Greco MF, Sheehan N, Thompson J, Minelli C, et al. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the radial plot and radial regression. Int J Epidemiol. 2018;47:2100. https:\/\/doi.org\/10.1093\/ije\/dyy265.","journal-title":"Int J Epidemiol"},{"key":"14350_CR30","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/s41588-018-0164-2","volume":"50","author":"M Verbanck","year":"2018","unstructured":"Verbanck M, Chen CY, Neale B, Do R. Publisher correction: detection of widespread horizontal Pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50:1196. https:\/\/doi.org\/10.1038\/s41588-018-0164-2.","journal-title":"Nat Genet"},{"key":"14350_CR31","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10654-021-00757-1","volume":"36","author":"AR Carter","year":"2021","unstructured":"Carter AR, Sanderson E, Hammerton G, Richmond RC, Davey Smith G, Heron J, et al. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur J Epidemiol. 2021;36:465\u201378. https:\/\/doi.org\/10.1007\/s10654-021-00757-1.","journal-title":"Eur J Epidemiol"},{"key":"14350_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s42113-018-0011-7","volume":"2","author":"QF Gronau","year":"2019","unstructured":"Gronau QF, Wagenmakers EJ. Limitations of bayesian Leave-One-Out Cross-Validation for model selection. Comput Brain Behav. 2019;2:1\u201311. https:\/\/doi.org\/10.1007\/s42113-018-0011-7.","journal-title":"Comput Brain Behav"},{"key":"14350_CR33","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10654-017-0255-x","volume":"32","author":"S Burgess","year":"2017","unstructured":"Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32:377\u201389. https:\/\/doi.org\/10.1007\/s10654-017-0255-x.","journal-title":"Eur J Epidemiol"},{"key":"14350_CR34","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1053\/euhj.2001.2729","volume":"22","author":"E Grossman","year":"2001","unstructured":"Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and the risk of malignancies. Eur Heart J. 2001;22:1343\u201352. https:\/\/doi.org\/10.1053\/euhj.2001.2729.","journal-title":"Eur Heart J"},{"key":"14350_CR35","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","volume":"11","author":"I Sipahi","year":"2010","unstructured":"Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor Blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11:627\u201336. https:\/\/doi.org\/10.1016\/S1470-2045(10)70106-6.","journal-title":"Lancet Oncol"},{"key":"14350_CR36","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1097\/HJH.0b013e3282f3ef5e","volume":"26","author":"CI Coleman","year":"2008","unstructured":"Coleman CI, Baker WL, Kluger J, White CM. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens. 2008;26:622\u20139. https:\/\/doi.org\/10.1097\/HJH.0b013e3282f3ef5e.","journal-title":"J Hypertens"},{"key":"14350_CR37","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ypmed.2017.01.011","volume":"99","author":"T Dierssen-Sotos","year":"2017","unstructured":"Dierssen-Sotos T, G\u00f3mez-Acebo I, Palazuelos C, Rodriguez-Moranta F, P\u00e9rez-G\u00f3mez B, Fern\u00e1ndez Vazquez JP, et al. Relationship between drugs affecting the renin-angiotensin system and colorectal cancer: the MCC-Spain study. Prev Med. 2017;99:178\u201384. https:\/\/doi.org\/10.1016\/j.ypmed.2017.01.011.","journal-title":"Prev Med"},{"key":"14350_CR38","doi-asserted-by":"publisher","first-page":"k4209","DOI":"10.1136\/bmj.k4209","volume":"363","author":"BM Hicks","year":"2018","unstructured":"Hicks BM, Filion KB, Yin H, Sakr L, Udell JA, Azoulay L. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ. 2018;363:k4209. https:\/\/doi.org\/10.1136\/bmj.k4209.","journal-title":"BMJ"},{"key":"14350_CR39","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1001\/jamainternmed.2013.9071","volume":"173","author":"CI Li","year":"2013","unstructured":"Li CI, Daling JR, Tang MT, Haugen KL, Porter PL, Malone KE. Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern Med. 2013;173:1629\u201337. https:\/\/doi.org\/10.1001\/jamainternmed.2013.9071.","journal-title":"JAMA Intern Med"},{"key":"14350_CR40","doi-asserted-by":"publisher","first-page":"e0159672","DOI":"10.1371\/journal.pone.0159672","volume":"11","author":"I G\u00f3mez-Acebo","year":"2016","unstructured":"G\u00f3mez-Acebo I, Dierssen-Sotos T, Palazuelos C, P\u00e9rez-G\u00f3mez B, Lope V, Tusquets I, et al. The use of antihypertensive medication and the risk of breast Cancer in a Case-Control study in a Spanish population: the MCC-Spain study. PLoS ONE. 2016;11:e0159672. https:\/\/doi.org\/10.1371\/journal.pone.0159672.","journal-title":"PLoS ONE"},{"key":"14350_CR41","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10549-015-3311-9","volume":"150","author":"EE Devore","year":"2015","unstructured":"Devore EE, Kim S, Ramin CA, Wegrzyn LR, Massa J, Holmes MD, et al. Antihypertensive medication use and incident breast cancer in women. Breast Cancer Res Treat. 2015;150:219\u201329. https:\/\/doi.org\/10.1007\/s10549-015-3311-9.","journal-title":"Breast Cancer Res Treat"},{"key":"14350_CR42","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ijc.30066","volume":"139","author":"T Huang","year":"2016","unstructured":"Huang T, Poole EM, Eliassen AH, Okereke OI, Kubzansky LD, Sood AK, et al. Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer. Int J Cancer. 2016;139:291\u20139. https:\/\/doi.org\/10.1002\/ijc.30066.","journal-title":"Int J Cancer"},{"key":"14350_CR43","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ejogrb.2016.09.005","volume":"207","author":"D Bar","year":"2016","unstructured":"Bar D, Lavie O, Stein N, Feferkorn I, Shai A. The effect of metabolic comorbidities and commonly used drugs on the prognosis of patients with ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2016;207:227\u201331. https:\/\/doi.org\/10.1016\/j.ejogrb.2016.09.005.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"14350_CR44","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ygyno.2019.05.030","volume":"154","author":"BN Harding","year":"2019","unstructured":"Harding BN, Delaney JA, Urban RR, Weiss NS. Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer. Gynecol Oncol. 2019;154:426\u201331. https:\/\/doi.org\/10.1016\/j.ygyno.2019.05.030.","journal-title":"Gynecol Oncol"},{"key":"14350_CR45","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1002\/cncr.29392","volume":"121","author":"JL Watkins","year":"2015","unstructured":"Watkins JL, Thaker PH, Nick AM, Ramondetta LM, Kumar S, Urbauer DL, et al. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer. 2015;121:3444\u201351. https:\/\/doi.org\/10.1002\/cncr.29392.","journal-title":"Cancer"},{"key":"14350_CR46","doi-asserted-by":"publisher","first-page":"645","DOI":"10.4143\/crt.2019.509","volume":"52","author":"MA Cho","year":"2020","unstructured":"Cho MA, Jeong SY, Sohn I, Kim MS, Kang JH, Paik ES, et al. Impact of angiotensin receptor blockers, Beta blockers, calcium channel blockers and Thiazide diuretics on survival of ovarian Cancer patients. Cancer Res Treat. 2020;52:645\u201354. https:\/\/doi.org\/10.4143\/crt.2019.509.","journal-title":"Cancer Res Treat"},{"key":"14350_CR47","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/EDE.0000000000000814","volume":"29","author":"J Busby","year":"2018","unstructured":"Busby J, Mills K, Zhang SD, Liberante FG, Cardwell CR. Postdiagnostic calcium channel blocker use and breast Cancer mortality: A Population-based cohort study. Epidemiology. 2018;29:407\u201313. https:\/\/doi.org\/10.1097\/EDE.0000000000000814.","journal-title":"Epidemiology"},{"key":"14350_CR48","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.canep.2017.08.012","volume":"50","author":"CM Wright","year":"2017","unstructured":"Wright CM, Moorin RE, Chowdhury EK, Stricker BH, Reid CM, Saunders CM, et al. Calcium channel blockers and breast cancer incidence: an updated systematic review and meta-analysis of the evidence. Cancer Epidemiol. 2017;50:113\u201324. https:\/\/doi.org\/10.1016\/j.canep.2017.08.012.","journal-title":"Cancer Epidemiol"},{"key":"14350_CR49","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/emboj.2010.346","volume":"30","author":"R Iwasawa","year":"2011","unstructured":"Iwasawa R, Mahul-Mellier AL, Datler C, Pazarentzos E, Grimm S. Fis1 and Bap31 Bridge the mitochondria-ER interface to Establish a platform for apoptosis induction. EMBO J. 2011;30:556\u201368. https:\/\/doi.org\/10.1038\/emboj.2010.346.","journal-title":"EMBO J"},{"key":"14350_CR50","doi-asserted-by":"publisher","first-page":"e113649","DOI":"10.1371\/journal.pone.0113649","volume":"9","author":"DQ Guo","year":"2014","unstructured":"Guo DQ, Zhang H, Tan SJ, Gu YC. Nifedipine promotes the proliferation and migration of breast cancer cells. PLoS ONE. 2014;9:e113649. https:\/\/doi.org\/10.1371\/journal.pone.0113649.","journal-title":"PLoS ONE"},{"key":"14350_CR51","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10641963.2017.1288736","volume":"40","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Wang Q, Zhao X, Meng H, Yu J. Effect of antihypertensive drugs on breast cancer risk in female hypertensive patients: evidence from observational studies. Clin Exp Hypertens. 2018;40:22\u20137. https:\/\/doi.org\/10.1080\/10641963.2017.1288736.","journal-title":"Clin Exp Hypertens"},{"key":"14350_CR52","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/15548627.2017.1389822","volume":"14","author":"X Sun","year":"2018","unstructured":"Sun X, Yang Y, Zhong XZ, Cao Q, Zhu XH, Zhu X, et al. A negative feedback regulation of MTORC1 activity by the lysosomal Ca2\u2009+\u2009channel MCOLN1 (mucolipin 1) using a CALM (calmodulin)-dependent mechanism. Autophagy. 2018;14:38\u201352. https:\/\/doi.org\/10.1080\/15548627.2017.1389822.","journal-title":"Autophagy"},{"key":"14350_CR53","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/2001-1326-1-16","volume":"1","author":"MA Fini","year":"2012","unstructured":"Fini MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med. 2012;1:16. https:\/\/doi.org\/10.1186\/2001-1326-1-16.","journal-title":"Clin Transl Med"},{"key":"14350_CR54","doi-asserted-by":"publisher","first-page":"95","DOI":"10.18632\/oncoscience.357","volume":"4","author":"SL Rains","year":"2017","unstructured":"Rains SL, Amaya CN, Bryan BA. Beta-adrenergic receptors are expressed across diverse cancers. Oncoscience. 2017;4:95\u2013105. https:\/\/doi.org\/10.18632\/oncoscience.357.","journal-title":"Oncoscience"},{"key":"14350_CR55","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1158\/1078-0432.CCR-05-1698","volume":"12","author":"AK Sood","year":"2006","unstructured":"Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res. 2006;12:369\u201375. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1698.","journal-title":"Clin Cancer Res"},{"key":"14350_CR56","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40119-015-0035-1","volume":"4","author":"HW Leung","year":"2015","unstructured":"Leung HW, Hung LL, Chan AL, Mou CH. Long-Term use of antihypertensive agents and risk of breast cancer: A Population-Based Case-Control study. Cardiol Ther. 2015;4:65\u201376. https:\/\/doi.org\/10.1007\/s40119-015-0035-1.","journal-title":"Cardiol Ther"},{"key":"14350_CR57","first-page":"2953","volume":"17","author":"E Parada-Huerta","year":"2016","unstructured":"Parada-Huerta E, Alvarez-Dominguez T, Uribe-Escamilla R, Rodriguez-Joya J, Ponce-Medrano JD, Padron-Lucio S, et al. Metastasis risk reduction related with Beta-Blocker treatment in Mexican women with breast Cancer. Asian Pac J Cancer Prev. 2016;17:2953\u20137.","journal-title":"Asian Pac J Cancer Prev"},{"key":"14350_CR58","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1758834012439738","volume":"4","author":"TI Barron","year":"2012","unstructured":"Barron TI, Sharp L, Visvanathan K. Beta-adrenergic blocking drugs in breast cancer: a perspective review. Ther Adv Med Oncol. 2012;4:113\u201325. https:\/\/doi.org\/10.1177\/1758834012439738.","journal-title":"Ther Adv Med Oncol"},{"key":"14350_CR59","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/sj.jhh.1002075","volume":"20","author":"JA Largent","year":"2006","unstructured":"Largent JA, McEligot AJ, Ziogas A, Reid C, Hess J, Leighton N, et al. Hypertension, diuretics and breast cancer risk. J Hum Hypertens. 2006;20:727\u201332. https:\/\/doi.org\/10.1038\/sj.jhh.1002075.","journal-title":"J Hum Hypertens"},{"key":"14350_CR60","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.31557\/APJCP.2018.19.12.3525","volume":"19","author":"AM Alhanafy","year":"2018","unstructured":"Alhanafy AM, Labeeb A, Khalil A. The role of diuretics in treatment of aromatase inhibitors induced musculoskeletal symptoms in women with Non metastatic breast Cancer. Asian Pac J Cancer Prev. 2018;19:3525\u201331. https:\/\/doi.org\/10.31557\/APJCP.2018.19.12.3525.","journal-title":"Asian Pac J Cancer Prev"},{"key":"14350_CR61","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2147\/CMAR.S350854","volume":"14","author":"Y Fan","year":"2022","unstructured":"Fan Y, Khan NH, Farhan Ali Khan M, Ahammad MDF, Zulfiqar T, Virk R, et al. Association of hypertension and breast cancer: antihypertensive drugs as an effective adjunctive in breast Cancer therapy. Cancer Manag Res. 2022;14:1323\u20139. https:\/\/doi.org\/10.2147\/CMAR.S350854.","journal-title":"Cancer Manag Res"},{"key":"14350_CR62","doi-asserted-by":"publisher","first-page":"62545","DOI":"10.18632\/oncotarget.19117","volume":"8","author":"H Ni","year":"2017","unstructured":"Ni H, Rui Q, Zhu X, Yu Z, Gao R, Liu H. Antihypertensive drug use and breast cancer risk: a meta-analysis of observational studies. Oncotarget. 2017;8:62545\u201360. https:\/\/doi.org\/10.18632\/oncotarget.19117.","journal-title":"Oncotarget"},{"key":"14350_CR63","doi-asserted-by":"publisher","unstructured":"Santala EEE, Artama M, Pukkala E, Visvanathan K, Staff S, Murtola TJ. Antihypertensive drug use and the risk of ovarian Cancer death among Finnish ovarian Cancer Patients-A nationwide cohort study. Cancers (Basel). 2021;13:2087. https:\/\/doi.org\/10.3390\/cancers13092087.","DOI":"10.3390\/cancers13092087"},{"key":"14350_CR64","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ygyno.2021.09.009","volume":"163","author":"T Huang","year":"2021","unstructured":"Huang T, Townsend MK, Dood RL, Sood AK, Tworoger SS. Antihypertensive medication use and ovarian cancer survival. Gynecol Oncol. 2021;163:342\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2021.09.009.","journal-title":"Gynecol Oncol"},{"key":"14350_CR65","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ygyno.2020.03.028","volume":"157","author":"A Majidi","year":"2020","unstructured":"Majidi A, Na R, Dixon-Suen S, Jordan SJ, Webb PM. Common medications and survival in women with ovarian cancer: A systematic review and meta-analysis. Gynecol Oncol. 2020;157:678\u201385. https:\/\/doi.org\/10.1016\/j.ygyno.2020.03.028.","journal-title":"Gynecol Oncol"},{"key":"14350_CR66","doi-asserted-by":"publisher","first-page":"665617","DOI":"10.3389\/fonc.2021.665617","volume":"11","author":"ZY Wen","year":"2021","unstructured":"Wen ZY, Gao S, Gong TT, Jiang YT, Zhang JY, Zhao YH, et al. Post-Diagnostic Beta blocker use and prognosis of ovarian cancer: A systematic review and Meta-Analysis of 11 cohort studies with 20,274 patients. Front Oncol. 2021;11:665617. https:\/\/doi.org\/10.3389\/fonc.2021.665617.","journal-title":"Front Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14350-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14350-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14350-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:16:42Z","timestamp":1751354202000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14350-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14350"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14350-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"3 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1125"}}